Recent investigations demonstrated that HDAC-inhibitors (HDACi) display selective toxicity against tumor cells and sensitize cancer cells to the cytotoxic effects of conventional cytostatic drugs [4-6]. The gene discussed is HDAC9; the disease is neoplasm.